Hämoblastosen - B- und T-Zell-Lymphome (NHL) -

Aggressive B- und T-Zell-Lymphome - Weiterführende Informationen

Leitlinien und Studien

siehe indolente Lymphome

Literatur

• Corradini P et al: Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316-23
• Feugier P et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23: 4117–26
• Glass B et al: Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transpl 2004; 34: 391–7
• Hummel M et al: A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419–30
• Morschhauser F et al: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54–8
• Pfreundschuh M et al: CHOP like chemotherapy with rituximab vs CHOP like chemotherapy alone in young patients with good prognosis aggressive non-Hodgkin’s lymphoma: results of a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology 2006; 7: 379–91
• Reyes F et al: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1107–205